Following a surge of 52.47% during regular trading session on Tuesday, Polyrizon Ltd (NASDAQ: PLRZ) witnessed a dip of 12.02% ...

An update from Polyrizon Ltd. ( (PLRZ) ) is now available.

Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap ...

A hearing before the Panel was held on June 26, 2025. At the hearing, Polyrizon presented its plan to address Nasdaq’s concerns, including a commitment to avoid the use of overly complex or inherently ...

With this agreement, Polyrizon secures a reliable and compliant manufacturing source for the PL-14 clinical trial. The trial aims to evaluate the safety and efficacy of PL-14 as an allergy blocker ...

Investing.com -- Polyrizon Ltd. (NASDAQ: PLRZ) stock surged 41% following the announcement of encouraging preclinical results for its PL-14 Allergy Blocker, which demonstrated targeted deposition in ...

TipRanks Dec. 30, 2024, 04:00 PM 16:56 EST Polyrizon (PLRZ) files to sell 2.42M ordinary shares for holders ...

Raanana, Israel, March 11, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative ...

Polyrizon (PLRZ) announced the publication of a national phase patent application by the United States Patent and Trademark Office. The patent application encompasses key aspects of Polyrizon’s ...

Polyrizon expects to initiate clinical trials in the U.S. and Europe in late 2025 to early 2026, following the completion of preclinical work and the upcoming FDA consultation. About Polyrizon Ltd.

Polyrizon (PLRZ) said on Tuesday that it has received a notification letter from Nasdaq granting the company’s request for the continued listing of its securities on the Nasdaq Capital Market.